Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia (AML) After Allogeneic Stem Cell Transplantation

Trial Profile

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia (AML) After Allogeneic Stem Cell Transplantation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Decitabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2016 Last checked against ClinicalTrials.gov record.
    • 29 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 29 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top